Qiagen's high P/E ratio is worrisome due to its poor earnings forecast. Despite the high P/E, investors retain their shares, but this earnings growth rate may eventually impact the share price. The high P/E and future earnings predictions pose a substantial risk to shareholders and potential investors.
Qiagen's performance is strong due to strategic profit reinvestment, leading to significant earnings growth. Its respectable ROE contributes to a net income increase. Yet, forecasts anticipate a slowdown in future earnings growth.
快而精醫藥股票討論區
2023Q1營收下滑22.8%,營業利潤大幅下滑52%,淨利潤下滑45.3%,這已經是連續第四個季度營收和利潤下滑。
目前市盈率24.9,市盈率TTM已經上升到29.7,暫時缺乏吸引力。
暫無評論